15 Nov 2013
What Speech-Language Pathologists Need to Know About the Emerging Medical Treatments in Stuttering (Ep. 429)
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Google Podcasts | Stitcher | TuneIn | RSS
Gerald A. Maguire, MD joins Peter Reitzes to discuss what speech-language pathologists need to know about the emerging medical treatments in stuttering.
StutterTalk is excited to announce that this StutterTalk episode or course will be available for 0.10 CEUs for approximately six months, free of charge, through the National Stuttering Association. For complete details regarding the continuing education units being offered by the National Stuttering Association, go to the National Stuttering Association’s CEU page.
Take the CEU Test Here. (expired May 15, 2014)
Show/Course Notes:
Title: What Speech-Language Pathologists Need to Know About the Emerging Medical Treatments in Stuttering
Objectives: At the conclusion of the program, the learner shall be able to:
- Identify the new DSM 5 criteria for childhood onset fluency disorder (stuttering)
- Summarize available pharmacologic treatments for stuttering and related conditions.
- Cite how traditional speech therapy with people who stutter is commonly effected by the medical treatment of stuttering.
Presenter Bio — Gerald A. Maguire, MD, is Sr. Associate Dean of Medical Education, holds the Kirkup Endowed Chair in Stuttering Treatment and is Professor of Clinical Psychiatry at the University of California Irvine School of Medicine. Dr. Maguire is a regular guest on StutterTalk. His previous appearances are archived here. Contact Dr. Maguire directly via email: gerald.maguire@uci.edu.
Episode/Course Description: Stuttering has recently been reclassified in DSM 5 as Childhood Onset Fluency Disorder. Over the past decade, much has been learned regarding the neurophysiologic and genetic basis of stuttering. With such, methods for medical treatments have emerged. Such treatments can potentially be utilized when standard speech therapy techniques have not yielded full benefits or as an augmentation to such treatments.
Presenter’s Financial Disclosures: Research Grants: Otsuka, Merck. Speaking/Consulting: Lilly, Novartis, Merck, Sunovion, Assurex, Lundbeck, Otsuka, Takeda
9 Jan 2016
What Causes Stuttering with Dr. Gerald Maguire from UC Riverside School of Medicine and the Kirkup Center (Ep. 564)
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Google Podcasts | Stitcher | TuneIn | RSS
Today on StutterTalk we ask Dr. Gerald Maguire what causes stuttering? This is the fourth episode in a series on the cause of stuttering. Dr. Maguire discusses the cause of stuttering while also providing listeners with a research update and much more.
Dr. Maguire is Chair of Psychiatry in the University of California’s, Riverside School of Medicine and a professor of psychiatry. Dr. Maguire is the Kirkup Center Chair in Stuttering Treatment and considered by many to be the leading authority on the medical treatment of stuttering. Jerry is well-published in numerous psychiatric journals. His previous appearances on StutterTalk are archived here.
Dr. Maguire may be contacted via email: gerald.maguire@ucr.edu